European Commission Approves Crysvita for Infants with XLH

bir ses eklendi Health

2026-07-22 12:47:10 -

European regulators expanded healthcare options for young children living with rare genetic conditions today. Kyowa Kirin EMEA received regulatory clearance to treat infants suffering from XLH using Crysvita. Healthcare providers can now administer this rare bone disease treatment to babies aged one month to one year across the region. This approval expands access to vital medicine throughout...

0 Yorumlar 1 hisse senetleri 236 Views 0 önizleme